This blog is a boring, but sarcasm free (almost) list of a few of the well over 150 studies of current childhood vaccines.
Please feel free to share with those who do not believe, or refuse to acknowledge, that these exist. Some of your friends, relatives or colleagues may still choose to ignore them, or nitpick minor details so they do not have to abandon their narrative. However, no reasonable person could, with a straight face, state they did not happen.
Those that are truly intellectually curious, will be willing to read and/or listen. There will be those who are too self righteous to consider introspection.
Some will tie themselves up into knots trying to fit their agenda. Just hold your tongue, allow them time to digest the information. If one person’s mind is changed, and one less child dies from a preventable illness, it is worth sharing.
The list is extensive, probably (OK, definitely) boring, and by no means comprehensive. I have tried to include the largest study on each currently available childhood vaccine.
BTW, starting September 1st, 2026, I will be running a series on the history of each disease, pre and post vaccine.
Polio
One of, if not the largest double blind study in medical history.
The 1954 Salk polio vaccine trial, led by Dr. Thomas Francis Jr. of the University of Michigan and sponsored by the National Foundation for Infantile Paralysis, remains the largest medical field trial in history, enrolling roughly 1.8 million children (“Polio Pioneers”) across 44 U.S. states, Canada, and Finland (PMC; Bentley Historical Library, University of Michigan). The trial actually used two parallel designs: a true randomized, double-blind, placebo-controlled arm (roughly 200,000 children given Salk’s killed-virus vaccine and a similar number given an indistinguishable saline placebo, with neither families nor evaluating physicians told who received which) and a larger “observed-control” arm where second-graders got the vaccine while unvaccinated first- and third-graders served as comparison controls (PMC; University of Wisconsin Biostatistics). Francis announced the results on April 12, 1955, at the University of Michigan’s Rackham Auditorium, reporting the vaccine was about 80-90% effective against paralytic polio overall (with lower, roughly 60-70%, protection against poliovirus type 1 specifically, and over 90% against types 2 and 3), prompting immediate U.S. licensure and nationwide distribution that same day (The Clinical Times; CBS News). Because Francis was Salk’s former mentor but had no financial or authorship stake in the vaccine’s development, his independent evaluation was designed specifically to insulate the results from bias, and the trial’s randomized, double-blind, placebo-controlled methodology became a template for rigorous vaccine and drug evaluation for decades afterward (The Clinical Times; PubMed).
Measles
The 1966 Cooperative Measles Vaccine Field Trial, sponsored by the American Academy of Pediatrics, which enrolled 4,758 kindergarten and early-elementary children in a double-blind, placebo-controlled design comparing two inactivated-vaccine schedules against placebo; it found the combined killed-then-live vaccine regimen gave about 95% efficacy versus roughly 75% for inactivated vaccine alone after a year (AAP/CAPES). Smaller ones include a 1965 JAMA field trial in young U.S. school children that gave 296 kids an inactivated measles vaccine and 286 a placebo, finding 94% short-term protection that declined to 57% over 27 months (JAMA); a 1965 double-blind, placebo-controlled trial in Tegucigalpa, Honduras comparing Edmonston B and further-attenuated live measles strains against placebo in 300 children (American Journal of Public Health); and a 1962 WHO-sponsored double-blind trial in Chile testing the Edmonston B live-virus strain, with or without gamma globulin, against placebo in about 530 children (PMC).
Mumps
The largest double-blind, placebo-controlled mumps vaccine trial was conducted among first- and second-graders in North Carolina, testing the Jeryl Lynn strain live mumps vaccine — it enrolled 3,281 children total, with 2,965 receiving vaccine and 316 receiving placebo, and found 96% efficacy (5 mumps cases among vaccinees vs. 13 among controls in the 180 days after vaccination).
Rubella/MMR
The largest double-blind, placebo-controlled clinical trial investigating a rubella-containing vaccine evaluated 6,540 healthy Danish infants aged 5 to 7 months to explore the immunogenicity, reactogenicity, and potential indirect health impacts of early administration. Published across multiple papers, the trial randomized participants to receive either a standard dose of the measles-mumps-rubella (MMR) vaccine or an inert solvent placebo. Results indicated that early vaccination was entirely safe, demonstrating no significant statistical difference in composite reactogenicity, atopic diseases, or hospitalization rates for non-targeted infections between the vaccine and placebo cohorts. While the specific rubella antibody seroprotection rate reached 57% following this early timeline (compared to just 8% in the placebo group), combining the subsequent routine 15-month dose allowed 99% of the infants to successfully achieve complete immune conversion.
The original studies on stand-alone rubella, were to demonstrate non-shedding of the live virus vaccine strain to close contacts.
Hepatitis B
The earliest randomized, double-blind, placebo-controlled clinical trials of the plasma-derived hepatitis B vaccine in pediatric populations—primarily conducted in high-endemicity regions like Taiwan and China during the early 1980s—evaluated the efficacy of the vaccine in preventing perinatally transmitted infections. These pioneering studies enrolled newborn infants born to mothers positive for the hepatitis B surface antigen (HBsAg) or healthy children, tracking them against a control cohort that received an inert placebo injection. Results demonstrated that the vaccine was highly effective, yielding up to an 88% efficacy rate in preventing chronic HBsAg carrier status when administered alone at birth, and up to a 96% reduction in long-term carriage. Long-term fifteen-year follow-up data later confirmed the safety and durable immunogenicity established by these initial controlled baseline trials, reinforcing the medical consensus for universal early-childhood dosing programs.
Pertussis (Whooping Cough)
The massive National Institutes of Health-sponsored, double-blind trials conducted in Italy and Sweden in the early 1990s collectively enrolled over 25,000 infants to evaluate the real-world safety and efficacy of newly developed acellular pertussis vaccines. In these landmark studies, infants were randomly assigned to receive either the traditional whole-cell pertussis vaccine, advanced acellular formulations, or a placebo control consisting strictly of diphtheria and tetanus (DT) toxoids.The primary scientific findings revealed that the acellular formulations—especially the multi-component variants—offered exceptional protection against laboratory-confirmed whooping cough while producing a vastly superior safety profile compared to the whole-cell option. Conversely, infants in the whole-cell vaccine groups experienced significantly higher frequencies of high fevers, protracted crying spells, and local injection site swelling. Ultimately, the definitive efficacy data from this large placebo-controlled trial provided the foundational global evidence needed to permanently phase out whole-cell pertussis shots in favor of safer, modern acellular childhood immunizations.
Diptheria and Tetanus
The Sweden I Efficacy Trial (1986–1987), a randomized, double-blind, placebo-controlled study that enrolled 3,801 children, stands as a foundational trial that evaluated tetanus-containing formulations alongside experimental components. In this landmark assessment, infants received either an investigational multi-component vaccine or a control group placebo containing only diphtheria and tetanus (DT) toxoids to measure safety and comparative immune defense. The trial proved that the underlying tetanus and diphtheria toxoid components generated near-universal seroconversion with powerful antibody protections without producing any severe general or unexpected systemic side effects in the young recipients. Ultimately, the rigorous blinded data from the Sweden I study confirmed the absolute tolerability of the tetanus baseline, establishing a clear safety profile that allowed health agencies to safely incorporate it as a standard comparative control in subsequent global pediatric vaccine research.
Hib
The 1997 Gambian Efficacy Trial, which enrolled 42,848 infants to form the largest randomized, double-blind, placebo-controlled study of the Haemophilus influenzae type b (Hib) conjugate vaccine, rigorously evaluated the formulation’s impact on severe pediatric illness. In this massive field trial, infants sequentially received three primary doses of either the active Hib tetanus protein conjugate vaccine combined with routine childhood shots or a control group placebo. The primary clinical findings revealed that the vaccine achieved exceptional protective efficacy, reducing invasive Hib disease by 95% and preventing a substantial portion of severe childhood pneumonia cases. Safety monitoring demonstrated excellent tolerability with a minimal rate of adverse side effects that mirrored the baseline placebo arm.
Pneumococcal
The Northern California Kaiser Permanente Efficacy Trial, which monitored 37,868 infants between 1995 and 1999, stands as the largest randomized, double-blind, placebo-controlled study to evaluate the safety and clinical impact of the original heptavalent Prevnar vaccine (PCV7). In this extensive clinical investigation, healthy infants sequentially received four doses of either the active pneumococcal conjugate formulation or a control group placebo containing an experimental meningococcal conjugate candidate. The final datasets revealed that the vaccine achieved an exceptional 100% protective efficacy against vaccine-serotype invasive pneumococcal diseases in per-protocol populations, alongside demonstrating significant structural reductions in pediatric pneumonia and severe otitis media episodes. Long-term safety evaluations proved the formulation was completely tolerable, with local site reactions and systemic fever frequencies tracking similarly to the baseline control arm.
Rotavirus
The Rotavirus Efficacy and Safety Trial (REST) evaluated 68,038 healthy infants in a randomized, double-blind, placebo-controlled design to assess the oral pentavalent vaccine, RotaTeq. Participants received either three active doses or a liquid placebo, with a primary focus on monitoring for the rare bowel blockage known as intussusception. The final datasets proved that the vaccine carried an identical safety profile to the placebo control, while simultaneously delivering an exceptional 98% reduction in severe rotavirus hospitalizations.
Varicella (Chickenpox)
The 1980s Oka/Merck Varicella Vaccine Trial remains the foundational, largest pre-licensure randomized, double-blind, placebo-controlled study to evaluate the live-attenuated chickenpox vaccine in a highly vulnerable pediatric cohort. Conducted among 956 healthy children between the ages of 1 and 14 with no clinical history of the disease, the study randomized participants to receive either a single dose of the active Oka-strain formulation or an inert liquid placebo. Monitoring across successive chickenpox seasons revealed an exceptional 98% to 100% protective efficacy against laboratory-confirmed varicella, with all initial clinical cases occurring exclusively in the placebo arm. Long-term safety assessments proved the formulation was completely tolerable, showing no significant variation in mild side effects compared to the control group and demonstrating zero viral transmission to susceptible siblings.
Meningococcal Meningitis ACYW
The largest and most rigorous double-blind study is Sanofi’s MenQuadfi (MenACYW-TT) licensure package, comprising five to seven double-blind, randomized, multicenter phase 2/3 trials enrolling nearly 5,000–6,300 participants from toddlers through older adults, each comparing MenQuadfi’s antibody response head-to-head against already-licensed quadrivalent vaccines like Menactra and Menveo rather than against a true placebo. The broadest aggregated evidence base comes from a 2023 systematic review pooling 16 randomized controlled trials of quadrivalent conjugate vaccines totaling over 20,000 participants, which found the MenACWY-TT formulation to be significantly more immunogenic than the MenACWY-CRM and MenACWY-D. A genuine placebo trial, the 1973 Sudan field study of the monovalent serogroup A polysaccharide component, which vaccinated over 21,000 people against a tetanus-toxoid placebo and found zero meningitis cases in the vaccine arm versus 10 in the placebo arm.
Meningococcal Meningitis B
The Vesikari et al. (2013) pivotal Phase III trial, published in The Lancet, evaluated Novartis’s multicomponent Bexsero vaccine in 3,630 infants starting at two months old. This controlled study verified the vaccine’s safety and capacity to trigger strong, protective antibody levels when administered alongside routine childhood immunizations. Over a decade of subsequent real-world tracking—following the United Kingdom’s 2015 launch of the first national MenB immunization programme—has confirmed its real-world effectiveness, showing up to a 75% drop in invasive meningitis cases among vaccinated children.
Hepatitis A
The 1991 Monroe, New York trial, published in The New England Journal of Medicine, evaluated the efficacy of Merck’s inactivated hepatitis A vaccine (VAQTA) in a double-blind, placebo-controlled study involving 1,037 healthy children aged 2 to 16. Conducted in a community experiencing recurring outbreaks, the trial randomly assigned participants to receive either a single dose of the vaccine or a placebo. The vaccine demonstrated a 100% protective efficacy rate, as 25 cases of clinical hepatitis A emerged within the placebo cohort compared to zero cases in the vaccinated group, while proving to be safe and well-tolerated with no severe adverse reactions.
HPV
A 2007 multi-center randomized trial published in Pediatrics evaluated Merck’s quadrivalent human papillomavirus (HPV) vaccine in 1,781 sexually naive preadolescents and adolescents aged 9 to 15. This double-blind, placebo-controlled study randomly administered either the active vaccine or a saline placebo at zero, two, and six months, establishing that the series was safe and highly immunogenic. Over a decade of long-term follow-up data from this and related cohorts has confirmed that the robust antibody levels remain durable with virtually no breakthrough disease. Real-world tracking has now definitively linked this sustained immunity to an almost 100% reduction in precancerous lesions and a dramatic decrease in invasive cervical and anogenital cancers in adulthood.
Mic drop, couldn’t resist.